4-甲基恶唑-5-甲醛 | 159015-06-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-甲基恶唑-5-甲醛
• 英文名称: 4-methyloxazole-5-carbaldehyde
• 英文别名: 4-methyl-1,3-oxazole-5-carbaldehyde
• CAS: 159015-06-2
• 化学式: C₅H₅NO₂
• mdl: MFCD10700248
• 分子量: 111.1
• InChiKey: ANPKYBKHXNFMFD-UHFFFAOYSA-N

物化性质

• 沸点：
  188.0±20.0 °C(Predicted)
• 密度：
  1.189±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  4-甲基恶唑-5-甲醛 在 盐酸羟胺 、 potassium carbonate 作用下， 以 水 为溶剂， 生成 4-methyl-1,3-oxazole-5-carbaldehyde oxime
  参考文献：
  名称：

  Propionic acid derivatives

  摘要：

  本申请涉及用于治疗冠心病等疾病的新型有效的PPAR-alpha激活化合物及其制备。

  公开号：

  US20030032671A1
• 作为产物：
  描述：

  4-甲基恶唑-5-羰酰氯 在 Pd-BaSO₄ 氢气 作用下， 以 苯 为溶剂， 反应 26.0h， 以76%的产率得到4-甲基恶唑-5-甲醛
  参考文献：
  名称：

  Formylation of 2,5-Unsubsituted Oxazole: Preparation and Characterization of 2- and 5-Formyl-4-methyloxazoles

  摘要：

  Vilsmeier formylation of 4-methyloxazole (1) gave a mixture of 4-methyl-5-oxazolecarboxaldehyde (2) and 4-methyl-2-oxazolecarboxaldehyde (3) in 1:1 ratio. Both aldehydes were prepared unambiguously: aldehyde (2) by oxidation of 5-hydroxymethyl-4-methyloxazole (4) and reduction of chloride of 4-methyl-5-oxazolecarboxylic acid (5) and aldehyde (3) by n-butyllithium/DME procedure. Aldehyde (2) sublimes in a refrigerator while aldehyde (3) forms hydrate, 5-dihydroxymethyl-4-methyloxazole (8).

  DOI：

  10.3987/com-94-6693

文献信息

• Small molecule antagonists of the gonadotropin-releasing hormone (GnRH) receptor: Structure–activity relationships of small heterocyclic groups appended to the 2-phenyl-4-piperazinyl-benzimidazole template
  作者：Diane B. Hauze、Murty V. Chengalvala、Joshua E. Cottom、Irene B. Feingold、Lloyd Garrick、Daniel M. Green、Christine Huselton、Wenling Kao、Kenneth Kees、Joseph T. Lundquist、Charles W. Mann、John F. Mehlmann、John F. Rogers、Linda Shanno、Jay Wrobel、Jeffrey C. Pelletier

  DOI：10.1016/j.bmcl.2009.02.043

  日期：2009.4

  2-phenyl-4-piperazinyl-benzimidazole N-ethyluracil GnRH receptor antagonist 1 following oral administration in rats. A series of small heterocycles were appended to the 2-(4-tert-butylphenyl)-4-piperazinyl-benzimidazole template in place of the N-ethyluracil. Two imidazole analogues, 32 and 41, were shown to possess substantial in vitro potency at the target receptor (hGnRH IC50 = 7 and 18 nM, respectively)

  先前的报道描述了大鼠口服给药后2-苯基-4-哌嗪基-苯并咪唑N-乙基尿嘧啶GnRH受体拮抗剂1的血清LH抑制药理作用。一系列小杂环取代N-乙基尿嘧啶被附加到2-（4-叔丁基苯基）-4-哌嗪基-苯并咪唑模板上。已显示两种咪唑类似物32和41在靶受体上具有显着的体外效能（分别为hGnRH IC 50  = 7和18 nM）和水溶性（在pH 7.4下分别为55和100μg/ mL）。两种化合物在大鼠中均具有较高的口服生物利用度，其中32种具有较高的口服生物利用度。进一步检查了一个切除睾丸的大鼠模型的血清LH抑制的基础上增加了41分布的数量。口服32只睾丸切除的大鼠血清LH水平有降低的趋势。
• [EN] COMPOSITIONS AND METHODS OF MODULATING SHORT-CHAIN DEHYDROGENASE ACTIVITY<br/>[FR] COMPOSITIONS ET PROCÉDÉS DE MODULATION DE L'ACTIVITÉ DE LA DÉSHYDROGÉNASE À CHAÎNE COURTE
  申请人：UNIV CASE WESTERN RESERVE

  公开号：WO2016168472A1

  公开（公告）日：2016-10-20

  Compounds and methods of modulating 15-PGDH activity, modulating tissue prostaglandin levels, treating disease, diseases disorders, or conditions in which it is desired to modulate 15-PGDH activity and/or prostaglandin levels include 15-PGDH inhibitors described herein.

  本文描述的15-PGDH抑制剂包括化合物和调节15-PGDH活性的方法，调节组织前列腺素水平，治疗疾病、疾病障碍或需要调节15-PGDH活性和/或前列腺素水平的情况。
• Versatile Photochemical Reactivity of Diverse Substituted 2-, 4- and 5-(<i>o</i> -Vinylstyryl)oxazoles
  作者：Ivana Šagud、Marija Šindler-Kulyk、Dragana Vojnović-Jandrić、Željko Marinić

  DOI：10.1002/ejoc.201701551

  日期：2018.1.31

  To study the effects of the position of the hexatrienyl moiety on the oxazole ring, targeted substituted cis/trans‐2/4/5‐(2‐vinylstyryl)oxazoles have been synthesized and irradiated. These new vinylstyryl‐2/4/5‐oxazole derivatives showed diverse photochemical behavior and gave new functionalized oxazole and oxazoline polycyclic products.

  为研究六三烯基部分在恶唑环上的位置的影响，已合成并辐照了目标取代的顺式/反式-2 / 4 / 5-（2-乙烯基苯乙烯基）恶唑。这些新的乙烯基苯乙烯基-2-4 / 5-恶唑衍生物显示出多种光化学行为，并提供了新的官能化恶唑和恶唑啉多环产物。
• (1-phenyl-1-heterocyclyl)methanol and (1-phenyl-1-heterocyclyl
  申请人：Astra Aktiebolag

  公开号：US05712299A1

  公开（公告）日：1998-01-27

  The present invention relates to novel heterocyclic compounds having the general formula (1) ##STR1## wherein: X is O, S or Se; R.sub.1 is H, lower alkyl, lower alkoxy-lower alkyl, aryl-lower alkyl or CF.sub.3 ; R.sub.2 is H, lower alkyl, lower alkoxy-lower alkyl, aryl-lower alkyl or CF.sub.3 ; W is O, S, NH or N-lower alkyl; R.sub.3 is H, lower alkyl or lower acyl; Ar is phenyl, furyl, thienyl, naphthyl, pyridyl or pyrrolyl, optionally substituted by R.sub.6 ; R.sub.6 is one or more groups selected from lower alkyl, lower acyl, halogen, lower alkoxy, CF.sub.3, OH, NO.sub.2 or NR.sub.4 R.sub.5, wherein R.sub.4 and R.sub.5 independently are H, lower alkyl or lower acyl; geometrical and optical isomers and racemates thereof where such isomers exist, as well as pharmaceutically acceptable acid addition salts thereof and solvates thereof having therapeutic activity, processes and intermediates for their preparation, pharmaceutical formulations containing said compounds and the medicinal use of said compounds.

  本发明涉及具有一般式（1）的新异环化合物 ##STR1## 其中：X为O、S或Se；R.sub.1为H、较低的烷基、较低的烷氧基-较低的烷基、芳基-较低的烷基或CF.sub.3；R.sub.2为H、较低的烷基、较低的烷氧基-较低的烷基、芳基-较低的烷基或CF.sub.3；W为O、S、NH或N-较低的烷基；R.sub.3为H、较低的烷基或较低的酰基；Ar为苯基、呋喃基、噻吩基、萘基、吡啶基或吡咯基，或者经R.sub.6取代的；R.sub.6为从较低的烷基、较低的酰基、卤素、较低的烷氧基、CF.sub.3、OH、NO.sub.2或NR.sub.4R.sub.5中独立选择的一个或多个基团，其中R.sub.4和R.sub.5独立地为H、较低的烷基或较低的酰基；以及它们的几何和光学异构体和混合物，如果存在这种异构体，以及其药学上可接受的酸盐和溶剂化合物，具有治疗活性，它们的制备过程和中间体，含有所述化合物的药物配方和所述化合物的药用。
• Synthesis of oxazolyl- and furanyl-substituted imidazole hydrochlorides and methiodides
  作者：John Boulos、Jerome Schulman

  DOI：10.1002/jhet.5570350413

  日期：1998.7

  furanyl-2-substituted imidazoles have been synthesized by coupling the two ring systems via the dipolar cycloaddition of tosyl methyl isocyanide to the corresponding oxazolyl and furanyl aldimines in basic media. These substituted oxazolyl and furanylimidazole bases obtained in this manner were then subjected to hydrogen chloride gas and to methyl iodide to form the corresponding hydrochlorides and methyliodides

  通过在碱性介质中，将甲苯磺酰基甲基异氰化物的偶极环加成到相应的恶唑基和呋喃基醛亚胺上，通过偶极环加成两个环系统来合成恶唑基-5-和呋喃基-2-取代的咪唑。然后将以这种方式获得的这些取代的恶唑基和呋喃基咪唑碱分别经受氯化氢气体和甲基碘的作用，分别形成相应的盐酸盐和甲基碘化物。纯化所有化合物，鉴定其特征，然后测试毒蕈碱结合亲和力。生物学测试结果显示毒蕈碱受体亲和力和选择性低。